Research Roundup

Debbie Rigby rounds up the latest in research news

Reduction in Use of Risperidone for Dementia in Australia

Risperidone is the only antipsychotic approved in Australia for the management of the behavioural and psychological symptoms of dementia (BPSD). In June 2015, the TGA amended the indication to restrict use in BPSD to patients with Alzheimer’s dementia for a maximum 12-week duration. The TGA labelling changes were associated with a significant reduction in the rate and duration of use of risperidone for BPSD in veterans living in both the aged care and community settings, and in the general older Australian population.

Pharmacy 2019;7:100.


NSAID-induced reactions: classification, prevalence, impact, and management strategies

NSAIDs are the leading cause of hypersensitivity drug reactions, including rhinitis, asthma, rhinosinusitis, nasal polyposis, urticaria and/or angioedema, and anaphylaxis. This article provides information on identification, cross-tolerance and management of NSAID-induced hypersensitivity drug reactions.

Journal of Asthma and Allergy 2019;12:217–233.


NSAID use among residents in 68 residential aged care facilities 2014 to 2017

Data from 68 Australian residential aged care facilities shows high use of NSAID use among residents. Nearly one-quarter of 10,367 residents used at least one NSAID. A majority of oral NSAID users concomitantly used a PPI. Among residents with any oral NSAID use, 182/1088 (16.7%) had triple whammy medication use.

Pharmacoepidemiology & Drug Safety, first published 6 August 2019.


Role of NSAIDs in the Association between Osteoarthritis and Cardiovascular Diseases

Data from Canada shows peole with OA have a higher risk of developing CVD comapred to people without OA. Approximately 41% of the total effect of OA on increased CVD risk was mediated through NSAID use. The proportion mediated through NSAID was 23%, 56% and 64% for CHF, IHD and stroke, respectively.

Arthritis & Rheumatology, first published 6 August 2019.

Medscape summary


Previous GPs, practice staff value community pharmacy ‘safety net’
Next We're back

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.

No Comment

Leave a reply